N4 Pharma announces collaboration with SRI to target and treat cells in the human body that have been previously unreachable

BioSpace | 2024-04-26 | 翻译由动脉网AI生成，点击反馈



可切换为仅中文







April 25th, 2024: N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI, an independent nonprofit research institute based in Silicon Valley, California, to combine Nuvec with SRI’s proprietary FOX Three Molecular Guidance System™ (MGS) with the aim of co-marketing the combined technology.

2024年4月25日：N4 Pharma Plc（目标：N4P）是开发Nuvec®的专业制药公司，Nuvec®是一种新型递送系统，旨在携带核苷酸作为癌症治疗和疫苗开发，已与位于加利福尼亚州硅谷的独立非营利研究所SRI签订了研究合作协议，将Nuvec与SRI专有的FOX Three Molecular Guidance system™（MGS）相结合，以共同营销该组合技术。

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec® in order to increase intracellular delivery to specific target cells. On the back of the combined technology, N4 Pharma and SRI will work collaboratively to develop and pursue new business opportunities..

这些公司将合作进行研究，将SRI的MGS系统与Nuvec®结合，以增加向特定靶细胞的细胞内递送。在联合技术的支持下，N4 Pharma和SRI将合作开发和寻求新的商业机会。。

SRI's MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics. The system uses proprietary technology that enables the delivery of macromolecular payloads to the target cell and then on to subcellular locations within those cells.

SRI的MGS技术旨在克服阻止大分子生物治疗剂细胞内递送的细胞障碍。该系统使用专有技术，可以将大分子有效载荷传递到靶细胞，然后传递到这些细胞内的亚细胞位置。

SRI has demonstrated that the MGS technology can deliver more than a dozen types of payloads - from functional enzymes, antibodies, and nucleic acids (including siRNA, ASOs, and DNA) to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered unreachable, and therefore, untreatable. .

SRI已经证明，MGS技术可以将十几种类型的有效载荷-从功能酶，抗体和核酸（包括siRNA，ASO和DNA）到脂质体和纳米颗粒-传递到先前认为不可到达的靶向细胞内分子靶标位置，因此无法治疗。。

N4 Pharma’s silica nanoparticle Nuvec has an irregular surface structure that simply and effectively traps and protects the siRNA, RNA and DNA to help delivery to the cell membrane. Once inside the cell, the siRNA/RNA/DNA is released to enter the cellular machinery, resulting in the desired pathway response - protein silencing, protein transcription, or other immuno-response. .

N4 Pharma的二氧化硅纳米粒子Nuvec具有不规则的表面结构，可以简单有效地捕获和保护siRNA，RNA和DNA，以帮助传递到细胞膜。一旦进入细胞，siRNA/RNA/DNA就会被释放进入细胞机制，从而产生所需的途径反应-蛋白质沉默，蛋白质转录或其他免疫反应。。

Together, the combined technology holds the potential to pave the way for targeted, effective treatments and to help realize the full potential of precision healthcare.

综合起来，这项技术有可能为有针对性的有效治疗铺平道路，并有助于实现精准医疗的全部潜力。

Kathlynn Brown, President of SRI’s Biosciences division, commented: “We’re excited to work with N4 Pharma to advance nucleic acid therapies and expand the number of applications of their Nuvec nanoparticle technology using the FOX Three Platform. The key properties of Nuvec, including preventing enzymatic breakdown of nucleotides and large surface area allowing multiple copy number of cargo, together with the targeting provided by MGS, may significantly enhance the use of nucleotide therapies. This strategic partnership marks an exciting journey towards expanding treatment possibilities and transforming the landscape of biomedicine.”.

SRI生物科学部门总裁凯瑟琳·布朗（KathlynnBrown）评论道：“我们很高兴与N4 Pharma合作，利用FOX Three平台推进核酸疗法，扩大其Nuvec纳米颗粒技术的应用范围。Nuvec的关键特性，包括防止核苷酸的酶促分解和允许多拷贝货物的大表面积，以及MGS提供的靶向性，可能会显着提高核苷酸疗法的使用。这一战略合作伙伴关系标志着一令人兴奋的旅程，将扩大治疗可能性，改变生物医学的格局。”。

Nigel Theobald, Chief Executive Officer of the Company, commented: “We are delighted to be working with SRI and to have entered into this collaboration agreement. Combining our technologies successfully will lead to working with major pharma companies in the fields of oncology and vaccines with the exciting potential to develop novel products. SRI collaborates with a broad range of strategic partners from small and virtual biotechnology companies to top 10 pharmaceutical companies and other leading industry partners, which will give us unparalleled access to potential commercial partners on the back of any successful combined technology resulting from our research. This marks an exciting new chapter for N4 Pharma and I look forward to providing further updates as the research work progresses, as well as on our other work streams such as oral applications of Nuvec® and the development of ECP105 for an orphan indication with Nanogenics.”.

该公司首席执行官奈杰尔·西奥博尔德（Nigel Theobald）评论道：“我们很高兴与SRI合作，并签署了这项合作协议。将我们的技术成功结合，将与肿瘤学和疫苗领域的主要制药公司合作，具有开发新产品的令人兴奋的潜力。SRI与众多战略合作伙伴合作，从小型和虚拟生物技术公司到排名前十的制药公司和其他领先的行业合作伙伴，这将使我们能够凭借我们研究取得的任何成功的联合技术，与潜在的商业合作伙伴进行无与伦比的合作。这标志着N4制药公司进入了一个令人兴奋的新篇章，我期待着随着研究工作的进展以及我们其他工作流程（如口服）的进一步更新Nuvec®的应用和ECP105的开发，用于纳米遗传学的孤儿适应症。”。

The SRI biosciences group integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development. It has advanced more than 200 drugs to clinical trials, and 25 have reached the market. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs..

SRI生物科学集团将基础生物医学研究与药物和诊断发现以及临床前和临床开发相结合。它已将200多种药物推进临床试验，其中25种已上市。该部门专注于针对高度未满足的医疗需求的各种治疗领域的新型平台和计划。。

About SRI International

关于SRI International

SRI is an independent nonprofit research institute headquartered in Menlo Park, Calif., with a rich history of supporting government and industry. We create and deliver world-changing solutions for a safer, healthier, and more sustainable future. For more than 75 years, we have collaborated across technical and scientific disciplines to discover and develop groundbreaking products and technologies and bring innovations and ideas to the marketplace.

SRI是一家独立的非营利研究机构，总部位于加利福尼亚州门洛帕克，拥有丰富的支持政府和行业的历史。我们创造并提供改变世界的解决方案，以实现更安全、更健康、更可持续的未来。75多年来，我们一直在技术和科学领域进行合作，以发现和开发突破性的成果 产品和技术，为市场带来创新和想法。

Learn more at www.sri.com. SRI Contact: Kelly Brieger, Director-Media & Content, kelly.brieger@sri.com.

了解更多信息，请访问www.sri.com。sri联系人：Kelly Brieger，Media&Content董事，kelly.brieger@sri.com.

About N4 Pharma

关于N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens.

N4 Pharma是一家专业制药公司，使用其独特的二氧化硅纳米颗粒输送系统Nuvec®，开发了一种用于肿瘤学，基因治疗和疫苗的新型输送系统。N4 Pharma的商业模式是与在这些领域开发新型抗原的公司合作，使用Nuvec®作为这些抗原的递送载体。

As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market. For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com. .

随着这些产品通过临床前和临床计划的进展，N4 Pharma将寻求在产品上市后获得预付款、里程碑付款以及最终的版税付款。有关公司的更多信息，请访问www.n4pharma.com或登录investors.n4pharma.com。

For more information please contact:

有关更多信息，请联系：

N4 Pharma plc

N4制药公司

Nigel Theobald, CEO

Nigel Theobald，首席执行官

Luke Cairns, Executive Director

Luke Cairns，执行董事

Via N4 Pharma Investor Hub

通过N4 Pharma Investor Hub

登录investors.n4pharma.com